1. Ray P, Singh S, Gupta S. Topical antimicrobial therapy: Current status and challenges. Indian J Med Microbiol. 2019 Jul-Sep;37(3):299-308.
2. Ferrara M, Gatti F, Lockington D et al. Antimicrobials and antiseptics: Lowering effect on ocular surface bacterial flora – A systematic review. Acta Ophthalmol. 2024 May;102(3):e215-e228.
3. Bhat R, Dogra A, Chib S, et al. Development of Mupirocin-Impregnated Bacterial Cellulosic Transdermal Patches for the Management of Skin Infection. ACS Omega 2024 9 (5), 5496-5508.
4. Christy J, Gurnani B, Kaur K, Moutappa F. Contact lens warpage: Lost but found. Indian J Ophthalmol. 2020 Aug;68(8):1662.
5. Lin L, Lan W, Lou B, et al. (2017). Genus Distribution of Bacteria and Fungi Associated with Keratitis in a Large Eye Center Located in Southern China. Ophthalmic Epidemiology, 24(2),
90-96.
6. Zhu J, Wang S, Wang C, et al. Microbial synthesis of bacitracin: Recent progress, challenges, and prospects. Synth Syst Biotechnol. 2023 Apr 10;8(2):314-322.
7. Zaidi S, Singh SL, Khan AU. Exploring antibiofilm potential of bacitracin against Streptococcus mutans. Microb Pathog. 2020 Dec;149:104279.
8. Ganesan N, Mishra B, Felix L, Mylonakis E. Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus. Microbiol Mol Biol Rev. 2023 Jun
28;87(2):e0003722.
9. Li J, Xiao Y, Fan Q et al. Dietary Bacitracin Methylene Disalicylate Improves Growth Performance by Mediating the Gut Microbiota in Broilers. Antibiotics (Basel). 2022 Jun 17;11(6):818.
10. Ma J, Liu J, Zhang Y et al. Bacitracin resistance and enhanced virulence of Streptococcus suis via a novel efflux pump. BMC Vet Res. 2019 Oct 28;15(1):377.
11. Wang L, Liu L, Zhou X. Bacitracin-Ag Nanoclusters as a Novel Antibacterial Agent Combats Shigella flexneri by Disrupting Cell Membrane and Inhibiting Biofilm Formation. Nanomaterials
(Basel). 2021 Nov 1;11(11):2928.
12. Khattak RZ, Nawaz A, Alnuwaiser MA et al. Formulation, In Vitro Characterization and Antibacterial Activity of Chitosan-Decorated Cream Containing Bacitracin for Topical Delivery.
Antibiotics (Basel). 2022 Aug 25;11(9):1151.
13. Zhang Z, Guo J, He Y et al. An injectable double network hydrogel with hemostasis and antibacterial activity for promoting multidrug-resistant bacteria infected wound healing. Biomater Sci.
2022 Jun 14;10(12):3268-3281.
14. Desai M, Castells M. Anaphylactic shock to bacitracin irrigation during breast implant surgery. Ann Allergy Asthma Immunol. 2019 Feb;122(2):217-218.
15. Wang B, Zhan Q, Xiao Y et al. Mupirocin enhances the biofilm formation of Staphylococcus epidermidis in an atlE-dependent manner. Int J Antimicrob Agents. 2023 Oct;62(4):106904.
16. Twilley D, Reva O, Meyer D, Lall N. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr
11;13:862112.
17. Labrecque S, Shah S, Fergus D, Parry MF. Mupirocin susceptibility of staphylococci 2022: Is it time for a change in MRSA decolonization protocols? Am J Infect Control. 2023 Jul;51(7):725-728.
18. Tucaliuc A, Blaga AC, Galaction AI, Cascaval D. Mupirocin: applications and production. Biotechnol Lett. 2019 May;41(4-5):495-502.
19. Dadashi M, Hajikhani B, Darban-Sarokhalil D, van Belkum A, Goudarzi M. Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis. J Glob Antimicrob Resist.
2020 Mar;20:238-247.
20. Nellipudi J, Stone C. Intranasal Mupirocin to Reduce Surgical Site Infection Post Cardiac Surgery: A Review of the Literature. Cureus. 2023 Jan 12;15(1):e33678.
21. Sharara SL, Maragakis LL, Cosgrove SE. Decolonization of Staphylococcus aureus. Infect Dis Clin North Am. 2021 Mar;35(1):107-133.
22. Yan BX, Chen XY, Wang ZY et al. Mupirocin blocks imiquimod-induced psoriasis-like skin lesion by inhibiting epidermal isoleucyl-tRNA synthetase. Cell Commun Signal. 2022 Nov
22;20(1):185.
23. Almostafa MM, Elsewedy HS, Shehata TM, Soliman WE. Novel Formulation of Fusidic Acid Incorporated into a Myrrh-Oil-Based Nanoemulgel for the Enhancement of Skin Bacterial Infe-
ction Treatment. Gels. 2022 Apr 15;8(4):245.
24. DI Y, Bai J, Chi M, Fan W, Zhang X. [Construction of EF-G knockdown strain of Mycobacterium smegmatis and drug resistance analysis]. Sheng Wu Gong Cheng Xue Bao. 2022 Mar
25;38(3):1050-1060. Chinese.
25. Lorrot M., Bourrat E., Doit C. et al.. Infections superficielles de la peau et dermo-hypodermites bactériennes [Superficial skin infections and bacterial dermohypodermitis]. Arch Pediatr. 2014
Aug;21(8):906-12. French.
26. Cheung IMY, Horsburgh S, Ziaei M, Gokul A. Ocular Antibiotic Utilisation across Aotearoa/New Zealand. Antibiotics (Basel). 2023 Jun 4;12(6):1007.
27. Goudarzi M, Seyedjavadi S, Bagheri P, Dadashi M, Nasiri MJ. Prevalence and genetic characteristics of fusidic acid resistant Staphylococcus aureus clinical isolates: Emergence of t030 strains
carrying fusB in Tehran, Iran. Acta Microbiol Immunol Hung. 2023 Mar 23;70(2):126-133.
28. Yin N, Michel C, Makki N, et al. Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium,
2013 to 2023. Euro Surveill. 2024 May;29(19):2300668.
29. Hale SJM, Cameron AJ, Lux CA et al. Polymyxin B and ethylenediaminetetraacetic acid act synergistically against Pseudomonas aeruginosa and Staphylococcus aureus. Microbiol Spectr. 2024
Feb 6;12(2):e0170923.
30. Jean SS, Harnod D, Hsueh PR. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. Front Cell Infect Microbiol. 2022 Mar 15;12:823684.
31. Ardebili A, Izanloo A, Rastegar M. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant Gram-negative infections: is it
superior to polymyxin monotherapy? Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429.
32. Zhou F, Lin S, Zhang J et al. Enhancement of photodynamic bactericidal activity of curcumin against Pseudomonas Aeruginosa using polymyxin B. Photodiagnosis Photodyn Ther. 2022
Mar;37:102677.
33. Xi J, Jia P, Zhu Y et al. Antimicrobial susceptibility to polymyxin B and other comparators against Gram-negative bacteria isolated from bloodstream infections in China: Results from CAR-
VIS-NET program. Front Microbiol. 2022 Oct 6;13:1017488.
34. Jackson EA, Geer K. Acute Otitis Externa: Rapid Evidence Review. Am Fam Physician. 2023 Feb;107(2):145-151.
35. Brennan-Jones CG, Head K, Chong LY, Burton MJ, Schilder AG, Bhutta MF. Topical antibiotics for chronic suppurative otitis media. Cochrane Database Syst Rev. 2020 Jan 2;1(1):CD013051.
36. Tang J, Guan H, Dong W et al. Application of Compound Polymyxin B Ointment in the Treatment of Chronic Refractory Wounds. Int J Low Extrem Wounds. 2022 Sep;21(3):320-324.
37. Shivshetty N, Swift T, Pinnock A et al. Evaluation of ligand modified poly (N-Isopropyl acrylamide) hydrogel for etiological diagnosis of corneal infection. Exp Eye Res. 2022 Jan;214:108881.
38. Gemeinder JLP, Barros NR, Pegorin GS et al. Gentamicin encapsulated within a biopolymer for the treatment of Staphylococcus aureus and Escherichia coli infected skin ulcers. J Biomater Sci
Polym Ed. 2021 Jan;32(1):93-111.
39. Lee H, Kim SM, Rahaman MI et al. Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection. Transl Vis Sci Technol. 2023 May 1;12(5):16.
40. Mei F, Lin J, Liu M, Yang Y, Lin X, Duan F. Posttraumatic Bacillus cereus Endophthalmitis: Clinical Characteristics and Antibiotic Susceptibilities. J Ophthalmol. 2021 Mar 17;2021:6634179.
41. Meer EA, Patel SB, Herskowitz WBA, Briceño CA. The treatment of refractory periorbital dermatitis. Indian J Ophthalmol. 2023 Oct;71(10):3386-3393.
42. Wang P, Long Z, Yu Z et al. The efficacy of topical gentamycin application on prophylaxis and treatment of wound infection: A systematic review and meta-analysis. Int J Clin Pract. 2019
May;73(5):e13334.
43. Schafhauser T, Wibberg D, Binder A et al. Genome Assembly and Genetic Traits of the Pleuromutilin-Producer Clitopilus passeckerianus DSM1602. J Fungi (Basel). 2022 Aug 16;8(8):862.
44. Patel AB, Lighter J, Fulmer Y, Copin R, Ratner AJ, Shopsin B. Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus. Pediatr Infect
Dis J. 2021 Jul 1;40(7):637-638.
45. Gahlawat G, Tesfaye W, Bushell M et al. Emerging Treatment Strategies for Impetigo in Endemic and Nonendemic Settings: A Systematic Review. Clin Ther. 2021 Jun;43(6):986-1006.
46. Mutlu-Ağardan NB, Tort S, Aydoğduoğlu Ş, Kıymacı ME. A New Insight to Silver Sulfadiazine Antibacterial Dressings: Nanoparticle-Loaded Nanofibers for Controlled Drug Delivery. AAPS
PharmSciTech. 2022 Nov 30;24(1):8.
47. Baver Acaban M, Sarı A, Demirbağ HO, Ersöz G, Aktaş S. The effects of topical mafenide acetate application on skin graft survival in bacterial contaminated wounds. Burns. 2024 Mar;50(2):433-443.
48. Bagheri M, Zoric A, von Kohout M, Fuchs PC, Schiefer JL, Opländer C. The Antimicrobial Efficacy of Topically Applied Mafenide Acetate, Citric Acid and Wound Irrigation Solutions Lava-
nox and Prontosan against Pseudomonas aeruginosa. Antibiotics (Basel). 2024 Jan 3;13(1):42.
49. Nasrallah F, Brewer CF, Arkoulis N, Mabvuure NT. Strategies to prevent suppurative chondritis following auricular burns: a systematic review. J Wound Care. 2022 May 2;31(5):394-39